Lantheus Holdings Inc (NASDAQ:LNTH) Director Sam R. Leno Sells 3,950 Shares

Lantheus Holdings Inc (NASDAQ:LNTH) Director Sam R. Leno sold 3,950 shares of the firm’s stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $25.33, for a total value of $100,053.50. Following the completion of the transaction, the director now owns 49,580 shares in the company, valued at approximately $1,255,861.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

LNTH traded up $0.30 during midday trading on Wednesday, reaching $25.54. 766 shares of the company were exchanged, compared to its average volume of 335,260. The company has a current ratio of 4.57, a quick ratio of 3.82 and a debt-to-equity ratio of 3.16. Lantheus Holdings Inc has a one year low of $12.59 and a one year high of $26.40. The stock has a market cap of $982.92 million, a P/E ratio of 27.04, a price-to-earnings-growth ratio of 1.90 and a beta of 1.46.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Tuesday, April 30th. The medical equipment provider reported $0.28 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.25 by $0.03. Lantheus had a return on equity of 59.57% and a net margin of 12.17%. The firm had revenue of $86.51 million for the quarter, compared to analysts’ expectations of $86.80 million. As a group, equities analysts forecast that Lantheus Holdings Inc will post 1.11 EPS for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of the business. PNC Financial Services Group Inc. raised its position in shares of Lantheus by 51.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 1,694 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 575 shares during the period. Tyers Asset Management LLC acquired a new stake in Lantheus in the 1st quarter valued at approximately $39,000. Riverhead Capital Management LLC bought a new position in Lantheus in the first quarter valued at approximately $44,000. Financial Gravity Companies Inc. bought a new position in Lantheus in the fourth quarter valued at approximately $45,000. Finally, C M Bidwell & Associates Ltd. bought a new position in Lantheus in the first quarter valued at approximately $45,000. Hedge funds and other institutional investors own 92.56% of the company’s stock.

Several equities analysts recently issued reports on the company. TheStreet upgraded Lantheus from a “c+” rating to a “b” rating in a report on Monday, March 4th. BidaskClub cut Lantheus from a “strong-buy” rating to a “buy” rating in a report on Tuesday. Finally, Zacks Investment Research cut Lantheus from a “buy” rating to a “hold” rating in a report on Friday, February 15th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $23.33.

WARNING: “Lantheus Holdings Inc (NASDAQ:LNTH) Director Sam R. Leno Sells 3,950 Shares” was originally reported by WKRB News and is the sole property of of WKRB News. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

Featured Article: What are convertible shares? 

Insider Buying and Selling by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with's FREE daily email newsletter.